New combo tackles stubborn gut inflammation after colitis surgery
NCT ID NCT06916390
First seen May 13, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This study tests whether the drug guselkumab (Tremfya), with or without a low-processed-food diet, can help people with chronic pouchitis—a painful gut condition that can occur after surgery for ulcerative colitis. Twenty adults who have not responded to antibiotics will receive the drug for 48 weeks, and half will also follow a special diet. The main goal is to see if symptoms improve after 16 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POUCHITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
university hospitals Leuven
RECRUITINGLeuven, Vlaams-Brabant, 3000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Guselkumab (Tremfya) and a low-ultra-processed-food, high-fruit diet
What this could lead to
If it works, this could offer a new treatment option for people with chronic pouchitis who haven't responded to antibiotics.
What could go wrong
This is a small, early-phase trial with only 20 people, so results may not apply to everyone. The diet part is exploratory, and guselkumab's effect on pouchitis is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.